Navigation Links
Astellas Named Elite Winner for Employee Engagement and Commitment in 'Chicago's 101 Best and Brightest Companies to Work For' Competition
Date:8/11/2009

DEERFIELD, Ill., Aug. 11 /PRNewswire/ -- In a ceremony recognizing "Chicago's 101 Best and Brightest Companies to Work For," Astellas Pharma US, Inc. won an Elite award for employee engagement and commitment by the National Association for Business Resources (NABR). Astellas scored high in all 10 categories and was specifically recognized for the high level of employees' engagement and pride in the company.

"At Astellas, we understand that investment in our employees is vital to reaching our corporate goals and it is even more critical in these tough economic times," said Seigo Kashii, president and CEO of Astellas. "Being selected as 'Chicago's 101 Best and Brightest Companies to Work For' further validates our commitment to our employees and being a recognized employer of choice in the Chicago area and the pharmaceutical industry."

"We are honored to recognize the efforts of this year's 101 'Best and Brightest' companies. These companies have created impressive organizational value and business results through their policies and best practices in human resource management. This award has become a powerful recruitment tool in the drive to attract and retain exceptional employees," said Jennifer Kluge, NABR president.

The NABR's annual list of "Best and Brightest Companies" compiles the results of an independent research firm that evaluates each company's entry in the following categories: communication, community initiatives, compensation and benefits, diversity and multiculturalism, employee education and development, employee engagement and commitment, recognition and retention, small business, recruitment and selection, and work-life balance. The judges look for unique and creative thought processes with support from senior management and policy makers.

About Astellas

Astellas Pharma US, Inc., located in Deerfield, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. In the US, Astellas markets products in the areas of Immunology, Urology, Anti-Infectives, Cardiovascular and Dermatology. For more information about Astellas Pharma US, Inc., please visit our website at www.us.astellas.com.

About The National Association for Business Resources

The National Association for Business Resources (NABR) advocates and represents small and medium-sized businesses throughout the United States. NABR specializes in providing businesses the benefits, programs, services, and assistance required to operating as efficiently and successfully as possible. Best practice solutions are available to members in the areas of human resources, healthcare, legal, transaction, compliance, marketing, and office services. For more information about NABR and its offerings, please visit www.nationalbiz.org or call 1-866-321-1822.


'/>"/>
SOURCE Astellas Pharma US, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiome And Astellas Announce Regulatory Update
2. FDA Approves Additional Indication for Astellas MYCAMINE(R)
3. Astellas/GlaxoSmithKlines Vesicare Has Advantages Over Pfizers Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence
4. Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
5. Astellas Announces New Vice President of Marketing
6. Astellas Hires New Vice President of Compliance
7. Astellas Adds CNS Therapy Area Leader to Global R&D Team
8. Astellas Names Head of Global R&D Operations
9. NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM)
10. AUA Foundation names the 2009 Astellas Rising Stars in Urology award winners
11. Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
Breaking Medicine Technology: